Pharma & CDMOKOSPI 003220389 approvals148 trials

DAEWON PHARMACEUTICAL CO.,LTD

KOSPI-listed pharmaceutical company behind Coldwon cold medicine and Jangdaewon probiotics, developing a P-CAB drug pipeline.

Price

Change

Market cap

Business overview

Source: DART corporate disclosure

Founded in 1961 and listed on KOSPI in 1999, Daewon Pharmaceutical is a comprehensive pharmaceutical company spanning pharmaceuticals, cosmetics, and health functional foods. It sells Coldwon, Korea's first chewable cold medicine, and Jangdaewon, Korea's first organic-certified probiotic supplement, alongside contract manufacturing (CMO) for other drugmakers, finished-drug exports, and the SNP mask pack cosmetics brand of its subsidiary SD Biotechnology. Its licensed drug pipeline includes TU2670 for endometriosis (in-licensed from Tium Bio, European Phase 2a completed), the P-CAB drug DW-4421 for GERD co-developed with Yunovia (domestic Phase 3 ongoing), and the obesity treatment DW-4222 licensed from Glaceum (domestic Phase 2a completed), among several licensed pipeline programs.

Products & technology

ColdwonChewable cold medicine (OTC)
JangdaewonOrganic-certified probiotic health functional food
SNP mask packCosmetics (subsidiary SD Biotechnology)

Regulatory approvals

data.go.kr

388 Korean MFDS drug approvals · 1958–2026 / 1 Korean MFDS device approvals · 2018

MFDS drugColdaewon Lergytoc sol.(cetirizine hydrochloride)2026-07-02
Drug · OTC · Notification202601934
MFDS drugPancrawon Tab.2026-06-16
Drug · OTC · Approval202601702
MFDS drugTavalozet 1/10mg2026-05-20
Drug · Prescription · Approval202601474
MFDS drugTwofree Tab.2026-05-03
Drug · Prescription · Approval202601316
MFDS drugDubrugel Solution(Simethicone)2026-04-16
Drug · OTC · Approval202601107
MFDS drugJunod Pre-filled Syringe2026-03-31
Drug · Prescription · Approval202600898
MFDS drugUptava SR Tab.2026-02-25
Drug · Prescription · Approval202600577
MFDS drugTwynchlor Tab. 40/5/12.5mg(Telmisartan,Amlodipine,Chlorthalidone)2026-01-20
Drug · Prescription · Approval202600168
MFDS drugTwynchlor Tab. 80/5/12.5mg(Telmisartan,Amlodipine,Chlorthalidone)2026-01-20
Drug · Prescription · Approval202600169
MFDS drugTwynchlor Tab. 80/5/25mg(Telmisartan,Amlodipine,Chlorthalidone)2026-01-20
Drug · Prescription · Approval202600170
MFDS drugEnzadex Soft Capsule 40mg2025-12-23
Drug · Prescription · Approval202503368
MFDS drugSaccine Cataplasma(Diclofenac Sodium)2025-12-04
Drug · OTC · Notification202503165

Show 68 more

MFDS drugEmpajenta Tab. 10/5mg2025-11-28
Drug · Prescription · Approval202503120
MFDS drugSaccine Plaster2025-11-28
Drug · OTC · Notification202503121
MFDS drugDaewoncol ibu nose Soft Cap.2025-11-28
Drug · OTC · Notification202503123
MFDS drugEmpajenta Tab. 25/5mg2025-11-26
Drug · Prescription · Approval202503083
MFDS drugDaewonco ibu cough Soft Cap.2025-11-19
Drug · OTC · Notification202503021
MFDS drugDaewoncol ibu cold Soft Cap.2025-11-19
Drug · OTC · Notification202503022
MFDS drugDaewoncol cough Soft cap.2025-10-17
Drug · OTC · Notification202502688
MFDS drugDaewoncol cold Soft Cap.2025-10-17
Drug · OTC · Notification202502690
MFDS drugDaewoncol nose Soft Cap.2025-10-02
Drug · OTC · Notification202502618
MFDS drugCodaewon Plus Tab.2025-09-28
Drug · Prescription · Approval202502560
MFDS drugmy toktok care eye drops2025-08-04
Drug · OTC · Notification202502031
MFDS drugEmpasita M XR Tab. 5/50/750mg2025-07-30
Drug · Prescription · Approval202501987
MFDS drugEmpasita M XR Tab.12.5/50/750mg2025-07-30
Drug · Prescription · Approval202501988
MFDS drugEmpamet XR Tab. 5/1000mg2025-07-25
Drug · Prescription · Approval202501911
MFDS drugEmpamet XR Tab. 12.5/750mg2025-07-25
Drug · Prescription · Approval202501912
MFDS drugEmpamet XR Tab. 5/750mg2025-07-25
Drug · Prescription · Approval202501913
MFDS drugEmpamet XR Tab. 12.5/1000mg2025-07-25
Drug · Prescription · Approval202501914
MFDS drugColdaewon kids cold S Syrup2025-07-03
Drug · OTC · Notification202501659
MFDS drugEmpasita M XR Tab. 10/100/1000mg2025-06-20
Drug · Prescription · Approval202501536
MFDS drugEmpasita M XR Tab.25/100/1000mg2025-06-20
Drug · Prescription · Approval202501537
MFDS drugEmpasita Tab.10/100mg(Empagliflozin, Sitagliptin)2025-06-12
Drug · Prescription · Approval202501433
MFDS drugEmpasita Tab.25/100mg(Empagliflozin, Sitagliptin)2025-06-12
Drug · Prescription · Approval202501434
MFDS drugEmpamet XR Tab. 25/1000mg2025-04-03
Drug · Prescription · Approval202500781
MFDS drugEmpamet XR Tab. 10/1000mg2025-04-03
Drug · Prescription · Approval202500782
MFDS drugDaewon Cucurbit Soft Capsule Cap.2025-03-24
Drug · OTC · Notification202500661
MFDS drugV Cold Syrup2024-12-31
Drug · OTC · Notification202403109
MFDS drugV Cold K Syrup2024-12-16
Drug · OTC · Notification202402974
MFDS drugV Cough Syrup2024-12-13
Drug · OTC · Notification202402956
MFDS drugSaccine Cool gel(Piroxicam)2024-08-13
Drug · OTC · Notification202401954
MFDS drugCHAJALTHA Sol.2024-07-25
Drug · OTC · Notification202401797
MFDS drugTerrosa prefilled pen2024-07-08
Drug · Prescription · Approval202401682
MFDS drugNeuroginkgo Tab. 240mg2024-04-11
Drug · OTC · Notification202400818
MFDS drugLitozet Tablet 10/5mg(Ezetimibe, Atorvastatin calcium trihydrate)2024-03-21
Drug · Prescription · Approval202400588
MFDS drugTralitin combi XR Tab.2.5/750mg2024-03-12
Drug · Prescription · Approval202400516
MFDS drugTralitin combi XR Tab.2.5/1000mg2024-03-12
Drug · Prescription · Approval202400517
MFDS drugSPIRACTONE TAB. 25mg2023-10-16
Drug · Prescription · Approval202302921
MFDS drugColdaewon Nose-QS Syrup2023-10-16
Drug · OTC · Notification202302925
MFDS drugTralitin combi XR Tab.5/1000mg2023-10-13
Drug · Prescription · Approval202302914
MFDS drugColdaewon Night Syrup2023-09-27
Drug · OTC · Notification202302835
MFDS drugEmpamet tab. 12.5/1000mg2023-09-05
Drug · Prescription · Approval202302639
MFDS drugEmpamet tab. 12.5/850mg2023-09-05
Drug · Prescription · Approval202302640
MFDS drugEmpamet tab. 12.5/500mg2023-09-05
Drug · Prescription · Approval202302641
MFDS drugMonteleple tab.2023-08-25
Drug · Prescription · Approval202302521
MFDS drugJanupio Tab. 100/30mg(Sitagliptin/Pioglitazone)2023-07-31
Drug · Prescription · Approval202302301
MFDS drugJanupio Tab. 100/15mg(Sitagliptin/Pioglitazone)2023-07-31
Drug · Prescription · Approval202302302
MFDS drugDapasita-M SR tab.2023-06-30
Drug · Prescription · Approval202302018
MFDS drugDapasita-M SR tab. 5/50/500mg2023-06-30
Drug · Prescription · Approval202302019
MFDS drug5/50/1000mg2023-06-30
Drug · Prescription · Approval202302020
MFDS drugDapasita Tab. 10/100mg2023-06-07
Drug · Prescription · Approval202301759
MFDS drugTavalozet 4/10mg2023-05-25
Drug · Prescription · Approval202301671
MFDS drugTavalozet 2/10mg2023-05-25
Drug · Prescription · Approval202301672
MFDS drugDapasita-M SR tab. 10/100/1000mg2023-05-22
Drug · Prescription · Approval202301622
MFDS drugDAEWON HEDERA Syrup(Ivy Leaf 30% Ethanol Dried Extract(5~7.5->1))2023-02-10
Drug · OTC · Notification202300506
MFDS drugJanulitin Combi XR Tab. 50/750mg2023-01-02
Drug · Prescription · Approval202300021
MFDS drugDapawon M XR Tab. 10/500mg2022-11-18
Drug · Prescription · Approval202204139
MFDS drugDapawon M XR Tab. 5/1000mg2022-11-18
Drug · Prescription · Approval202204140
MFDS drugDapawon M XR Tab. 5/500mg2022-11-18
Drug · Prescription · Approval202204141
MFDS drugDapawon M XR Tab. 10/1000mg2022-11-16
Drug · Prescription · Approval202204123
MFDS drugmy toktok pure eye drop(single use)2022-08-23
Drug · OTC · Notification202203353
MFDS drugTolvis2022-07-28
Drug · Prescription · Approval202203114
MFDS drugTolvis2022-07-28
Drug · Prescription · Approval202203115
MFDS drugJanuritin Combi XR Tab. 50/500mg2022-05-11
Drug · Prescription · Approval202201933
MFDS drugJanuritin Combi XR Tab. 50/1000mg2022-05-11
Drug · Prescription · Approval202201934
MFDS drugJanuritin Combi XR Tab. 100/1000mg2022-05-11
Drug · Prescription · Approval202201935
MFDS drugSemerwon Tab.2022-04-29
Drug · Prescription · Approval202201762
MFDS drugGane-Won Soft Cap. 350mg2022-04-07
Drug · OTC · Notification202201483
MFDS drugTENETIN M SR 20/1000mg2022-04-04
Drug · Prescription · Approval202201330
MFDS drugTENETIN M SR 10/750mg2022-04-04
Drug · Prescription · Approval202201331

Showing the 80 most recent of 389 records.

Clinical trials

data.go.kr

148 MFDS clinical trial authorisations · 2012–2026 (Phase 1 63 · Bioequivalence 54 · Phase 3 21 · Phase 2 5 · Phase 2a 2)

Phase 1DW44212026-06-12
1 trial site
BioequivalenceDW6521-T12026-05-15
1 trial site
Phase 1DW44212026-01-12
1 trial site
Phase 1DW44212025-12-30
1 trial site
Phase 1DW55242025-11-26
1 trial site
Phase 1DW44212025-11-06
1 trial site
Phase 3DW44212025-10-27
20 trial sites
Phase 3DW44212025-10-15
18 trial sites
Phase 1DW44212025-09-29
1 trial site
BioequivalenceDW65212025-09-10
1 trial site
Phase 1DW54212025-07-28
2 trial sites
BioequivalenceDW65212025-03-27
1 trial site

Show 68 more

Phase 1DW51242025-02-07
1 trial site
BioequivalenceDW-22222024-12-13
1 trial site
Phase 1DW44212024-10-09
2 trial sites
Phase 3DW54212024-08-26
18 trial sites
Phase 3DW18072024-05-14
21 trial sites
Phase 1DW12222024-04-09
1 trial site
Phase 1DW12222024-04-08
1 trial site
Bioequivalence엠파젠타정 25/5밀리그램2024-03-11
2 trial sites
Phase 1DW10222024-03-04
3 trial sites
Phase 1DW12222024-02-08
1 trial site
Phase 2DW44212024-02-08
9 trial sites
Phase 1DW12222024-01-24
1 trial site
Phase 1DW10262024-01-18
2 trial sites
Phase 3DW51212023-11-30
8 trial sites
Phase 1DW11222023-09-18
2 trial sites
Phase 1DW11222023-09-07
2 trial sites
BioequivalenceDW21222023-08-14
1 trial site
Phase 1DW11222023-08-08
2 trial sites
Phase 1DW11222023-08-02
2 trial sites
Phase 1DW10212023-07-04
1 trial site
BioequivalenceDW51252023-02-27
2 trial sites
BioequivalenceDW51222022-12-29
2 trial sites
Phase 1DW51212022-11-29
1 trial site
Phase 1DW1125, DW1125A2022-08-16
2 trial sites
Phase 1DW10262022-07-25
2 trial sites
Bioequivalence에스원엠프정40mg2022-07-19
2 trial sites
Phase 3DW10262022-06-27
26 trial sites
BioequivalenceDWCLDS1252022-06-21
2 trial sites
BioequivalenceDW51252022-05-30
2 trial sites
BioequivalenceDW52212022-05-13
2 trial sites
BioequivalenceDW51222022-05-13
2 trial sites
BioequivalenceDWCLDS2502022-04-18
2 trial sites
Phase 3DW1125, DW1125A2022-04-01
25 trial sites
Bioequivalence엠파젠타정 25/5밀리그램2022-03-25
2 trial sites
Phase 1DW43012022-03-10
2 trial sites
Bioequivalence핀카정2022-01-17
2 trial sites
Bioequivalence에스원엠프정40mg2022-01-14
2 trial sites
Phase 1DW10252021-12-02
2 trial sites
Phase 2DWTG51012021-11-02
4 trial sites
Phase 1DW10292021-07-02
1 trial site
Phase 2/3DW17042021-06-14
9 trial sites
Phase 1DW18052021-05-18
1 trial site
Phase 2DW43012021-04-20
7 trial sites
Phase 1DW18052021-04-13
1 trial site
Phase 3DWKH2021-01-29
8 trial sites
Bioequivalence에스원엠프정40mg2021-01-04
2 trial sites
Phase 2DW49022020-10-21
12 trial sites
Phase 3DW19032020-10-13
27 trial sites
Phase 1DW18062020-08-11
2 trial sites
Phase 1DW1808-T1, DW1808-T22020-07-23
2 trial sites
Phase 1DW1808-T1, DW1808-T22020-07-17
2 trial sites
Phase 1DW19022020-07-10
2 trial sites
Bioequivalence칸디나캡슐(플루코나졸)2020-07-02
2 trial sites
Phase 1DW1809-T22020-07-02
2 trial sites
Phase 1DW18092020-06-24
2 trial sites
Phase 1DW18072020-05-14
2 trial sites
Bioequivalence원살탄플러스에프정2020-05-12
2 trial sites
BioequivalenceDW28012020-05-08
2 trial sites
BioequivalenceDW2802-T2020-04-22
2 trial sites
Phase 1DW19022020-03-30
2 trial sites
Phase 1DW19032020-03-10
1 trial site
Phase 3펠루비서방정(펠루비프로펜)2020-02-04
12 trial sites
Phase 1DW18062020-01-03
2 trial sites
Phase 1DW18092019-10-31
2 trial sites
Phase 1DW18072019-10-11
1 trial site
Phase 1DW15032019-10-08
2 trial sites
Phase 1bDW43012019-10-04
2 trial sites
Bioequivalence알포콜린연질캡슐(콜린알포세레이트)2019-09-30
2 trial sites

Showing the 80 most recent of 148 records.

R&D and key agreements

Source: DART corporate disclosure

TU2670 · 자궁근종/자궁내막증 · 국내 2상(자궁근종) 종료, 유럽 2a상(자궁내막증) 종료 · Domestic exclusive license from Tium Bio's NCE403 program candidate

DW-4121 · 폐암 · 국내 1상 준비중, 유럽 1상 준비중 · CAGE inhibition mechanism; licensed from L base under a 2021 agreement (KRW 1bn upfront paid)

DW-4222 · 비만 · 국내 2a상 완료 · PON2-binding mechanism enhancing mitochondrial function; licensed from Glaceum (2022)

DW-4321 · 당뇨·비만 · 후보물질발굴단계 · Triple agonist (GLP-1/GIP/GCG); joint research and license agreement with Farmus Bioscience (2023)

DW-4421 · 위식도역류질환(미란성·비미란성) · 국내 2상 종료, 국내 3상 진행중 · P-CAB (potassium-competitive acid blocker); co-developed and licensed with Yunovia (2024)

AI reads

MAA server logs · IP-verified

Read to answer a question

Someone asked an AI a question, and it fetched this page live to answer.

Crawled for indexing

Collected for later use. Not a signal of interest.

0answer

index 2

Last 7 days

0answer

index 2

Last 30 days

0answer

index 2

All time

OpenAIOAI-SearchBot2

Measured since Aug 25, 2026 · 1 AI engines · last read Aug 25, 2026

User-agent strings can be forged, so we do not count them at face value. We count only requests matched against vendor-published IP ranges, or confirmed by forward-verified reverse DNS.

Connect this index to your AI tool →

Not yet compiled: business overview. Send us materials and we will add them

Company facts

Founded: 1961
Listed: 1999
Market: KOSPI 003220
CEO: 백승열
Location: Seoul
Category: Pharma & CDMO

Performance

Consolidated · DART

Year	Revenue	Op. profit
2025	₩605.4B	₩3.5B
2024	₩598.2B	₩28.2B
2023	₩527.0B	₩32.2B

AI visibility

2026-08-13

85/ 100

✓Crawler access

✓Structured data

✗Sitemap

✓HTTPS

✓English pages

✗llms.txt

Keywords

cold-medicineprobioticsp-cablicense-inkospicmo

Companies approved for the same productsPharma & CDMO

Ranked by how many MFDS product categories overlap. Not a ranking — a pointer to where to look.

Celltrion Pharm Inc.1 shared

Celltrion Pharm holds exclusive domestic distribution rights for 12 Celltrion biologics and manufactures the liver drug Godex.

IL DONG PHARMACEUTICAL CO., LTD.1 shared

Founded and listed on the KOSPI in 2016, Il Dong Pharmaceutical manufactures products including the Aronamin vitamin line.

SHINHUNG CO.,LTD1 shared

Founded in 1964 and KOSPI-listed in 1991, Shinhung manufactures and distributes dental equipment and materials.

Yuyu Pharma, Inc.100

Founded in 1941 and listed on the KOSPI in 1975, Yuyu Pharma is a pharmaceutical company with a co-promotion agreement with Dong-A ST for Tanamin.

ILDONG HOLDINGS CO.,LTD100

Founded in 1941 and listed on the KOSPI in 1975, Ildong Holdings is the holding company of the Ildong Pharmaceutical Group, overseeing pharmaceutical, aesthetic medical device, and drug development affiliates.

Medy-Tox Inc.99

Founded 2000, KOSDAQ-listed 2009, Medy-Tox develops and exports botulinum toxin biopharmaceuticals including Meditoxin and Innotox.

GC Biopharma Corp.97

KOSPI-listed comprehensive pharmaceutical company specializing in blood products and vaccines, with FDA-approved immunoglobulin ALYGLO.

BIO-FD&C CO.,LTD.85

Founded 2005, KOSDAQ-listed 2022, BIO-FD&C develops plant-cell platform-based cosmeceutical materials and biopharma pipelines.

SAMSUNG BIOLOGICS CO.,LTD.85

Founded 2011, listed 2016 — Samsung Biologics is a biopharma CDMO with 785,000L capacity across five Songdo plants.

GENOLUTION INC.85

Founded in 2006 and listed on KOSDAQ in 2020, Genolution is a molecular diagnostics and RNAi company producing nucleic acid extraction reagents and devices.

HANDOK Inc.85

KOSPI-listed comprehensive pharma company behind Amaryl diabetes drug and the USD 86.25M HL5101 anticancer out-license deal.

HL GENOMICS Co., Ltd.85

Sources and updates

Company basics: Korea Exchange · DART
Business content: Compiled from disclosure filings
AI visibility: Measured 2026-08-13

This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.

Request a correction or addition